In fact, while the inhibition of BRAF or of combined BRAF/MEK initially reduced the tumor progression in BRAFV600E mutant melanoma patients, the targeted therapy resistance emerged in most of them within 1 or 2 years, via several mechanisms. This evidence concerns the gene MAP2K7 and neoplasm.